Enlarged cavum septum pellucidum and small thymus as markers for 22q11.2 deletion syndrome
- PMID: 38497811
- DOI: 10.1002/pd.6555
Enlarged cavum septum pellucidum and small thymus as markers for 22q11.2 deletion syndrome
Abstract
Background: Enlarged cavum septum pellucidum (CSP) and hypoplastic thymus are proposed extra-cardiac fetal markers for 22q11.2 deletion syndrome. We sought to determine if they were part of the fetal phenotype of our cohort of fetuses with 22q11.2 deletion syndrome.
Methods: Case-control study of fetuses evaluated from 2016 to 2022. The study group included fetuses with laboratory confirmation of 22q11.2 deletion syndrome. The control group included pregnancies with conotruncal cardiac anomalies with normal microarray as well as structurally normal fetuses with normal microarray. The CSP and thymus were routinely measured during anatomical ultrasound in all patients at their initial visit at 27.1 ± 4.7 weeks. The CSP and thymus measurements were classified as abnormal if they were >95% or <5% for gestational age, respectively. The groups were compared using analysis of variance or Kruskal-Wallis for continuous variables and Fisher's exact test for categorical variables. Logistic regression was performed, and a Receiver Operating Characteristic (ROC) curve was constructed.
Results: We identified 47 fetuses with 22q11.2 deletion syndrome and compared them to 47 fetuses with conotruncal anomalies and normal microarray and 47 structurally normal fetuses with normal microarray. 51% (24/47) of fetuses with 22q11.2 deletion syndrome had an enlarged CSP compared to 6% (3/47) of fetuses with a conotruncal anomaly and normal microarray and none of the structurally normal fetuses (p < 0.001). Of the fetuses with 22q11.2 deletion syndrome, 83% (39/47) had a hypoplastic or absent thymus compared to 9% (4/47) of the fetuses with a conotruncal anomaly and normal microarray and none of the structurally normal fetuses (p < 0.001). 87% (41/47) of the fetuses with 22q11.2 deletion syndrome had conotruncal cardiac anomalies. Logistic regression revealed that both enlarged CSP and hypoplastic/absent thymus were associated with 22q11.2 deletion syndrome. The area under the ROC curve for the two markers was 0.94.
Conclusion: An enlarged CSP and hypoplastic/absent thymus appear to be part of the fetal phenotype of 22q11.2 deletion syndrome. These markers are associated with conotruncal anomalies in the setting of 22q11.2 deletion syndrome but not in normal controls or fetuses with conotruncal defects and normal microarrays.
© 2024 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Similar articles
-
Utility of Measuring Fetal Cavum Septum Pellucidum (CSP) Width During Routine Obstetrical Ultrasound for Improving Diagnosis of 22q11.2 Deletion Syndrome: A Case-Control Study.Appl Clin Genet. 2022 Jul 26;15:87-95. doi: 10.2147/TACG.S364543. eCollection 2022. Appl Clin Genet. 2022. PMID: 35923603 Free PMC article.
-
Dilated cavum septi pellucidi in fetuses with microdeletion 22q11.Prenat Diagn. 2016 Oct;36(10):911-915. doi: 10.1002/pd.4911. Epub 2016 Aug 30. Prenat Diagn. 2016. PMID: 27502038
-
Absent or hypoplastic thymus on ultrasound: a marker for deletion 22q11.2 in fetal cardiac defects.Ultrasound Obstet Gynecol. 2002 Dec;20(6):546-52. doi: 10.1046/j.1469-0705.2002.00864.x. Ultrasound Obstet Gynecol. 2002. PMID: 12493042
-
Evaluation and Significance of Nonvisualization of the Cavum Septum Pellucidum on Prenatal Ultrasonography.Obstet Gynecol Surv. 2024 Aug;79(8):477-483. doi: 10.1097/OGX.0000000000001296S. Obstet Gynecol Surv. 2024. PMID: 39136638 Review.
-
Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.Genes (Basel). 2023 Jan 6;14(1):160. doi: 10.3390/genes14010160. Genes (Basel). 2023. PMID: 36672900 Free PMC article. Review.
References
REFERENCES
-
- McDonald‐McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Prim. 2015;1:15071. https://doi.org/10.1038/nrdp.2015.71
-
- Edelmann L, Pandita RK, Morrow BE. Low‐copy repeats mediate the common 3‐Mb deletion in patients with velo‐cardio‐facial syndrome. Am J Hum Genet. 1999;64(4):1076‐1086. https://doi.org/10.1086/302343
-
- Shaikh TH, Kurahashi H, Saitta SC, et al. Chromosome 22‐specific low copy repeats and the 22q11.2 deletion syndrome: genomic organization and deletion endpoint analysis. Hum Mol Genet. 2000;9(4):489‐501. https://doi.org/10.1093/hmg/9.4.489
-
- McDonald‐McGinn DM, Tonnesen MK, Laufer‐Cahana A, et al. Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net. Genet Med. 2001;3(1):23‐29. https://doi.org/10.1097/00125817‐200101000‐00006
-
- Grati FR, Molina Gomes D, Ferreira JC, et al. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn. 2015;35(8):801‐809. https://doi.org/10.1002/pd.4613
MeSH terms
Substances
LinkOut - more resources
Full Text Sources